Tags

Type your tag names separated by a space and hit enter

Mutagenicity studies on fenitrothion in bacteria and mammalian cells.
Mutat Res. 1989 Jan; 222(1):53-61.MR

Abstract

The mutagenicity of fenitrothion was determined in strains of Salmonella typhimurium and Escherichia coli. Fenitrothion was found to be non-mutagenic in Salmonella typhimurium strains of TA98, TA1535 and TA1537 and in Escherichia coli WP2uvrA both with and without S9 mix, while weak mutagenicity was observed only in Salmonella typhimurium TA100 and enhanced by the addition of S9 mix. The mutagenicity observed in the TA100 strain was not expressed in a nitroreductase-deficient strain, TA100 NR, and decreased in a transacetylase-deficient strain, TA100 1,8-DNP6. The mutagenicity of fenitrothion was also examined by a gene mutation assay using the gene for hypoxanthine-guanine phosphoribosyltransferase (hgprt) in V79 Chinese hamster lung cells. Fenitrothion did not induce any increment of 6-thioguanine-resistant mutant cells at doses ranging from 0.01 to 0.3 mM regardless of the presence or absence of S9 mix. These results suggest that reduction of fenitrothion by a bacterial nitroreductase of TA100 to an active form is essential for the expression of the mutagenicity of fenitrothion in TA100 and that a bacterial transacetylase of TA100 also has an important role in the process of mutagenic activation.

Authors+Show Affiliations

Laboratory of Biochemistry and Toxicology, Sumitomo Chemical Co., Ltd., Osaka, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

2643032

Citation

Hara, M, et al. "Mutagenicity Studies On Fenitrothion in Bacteria and Mammalian Cells." Mutation Research, vol. 222, no. 1, 1989, pp. 53-61.
Hara M, Kogiso S, Yamada F, et al. Mutagenicity studies on fenitrothion in bacteria and mammalian cells. Mutat Res. 1989;222(1):53-61.
Hara, M., Kogiso, S., Yamada, F., Kawamoto, M., Yoshitake, A., & Miyamoto, J. (1989). Mutagenicity studies on fenitrothion in bacteria and mammalian cells. Mutation Research, 222(1), 53-61.
Hara M, et al. Mutagenicity Studies On Fenitrothion in Bacteria and Mammalian Cells. Mutat Res. 1989;222(1):53-61. PubMed PMID: 2643032.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mutagenicity studies on fenitrothion in bacteria and mammalian cells. AU - Hara,M, AU - Kogiso,S, AU - Yamada,F, AU - Kawamoto,M, AU - Yoshitake,A, AU - Miyamoto,J, PY - 1989/1/1/pubmed PY - 1989/1/1/medline PY - 1989/1/1/entrez SP - 53 EP - 61 JF - Mutation research JO - Mutat Res VL - 222 IS - 1 N2 - The mutagenicity of fenitrothion was determined in strains of Salmonella typhimurium and Escherichia coli. Fenitrothion was found to be non-mutagenic in Salmonella typhimurium strains of TA98, TA1535 and TA1537 and in Escherichia coli WP2uvrA both with and without S9 mix, while weak mutagenicity was observed only in Salmonella typhimurium TA100 and enhanced by the addition of S9 mix. The mutagenicity observed in the TA100 strain was not expressed in a nitroreductase-deficient strain, TA100 NR, and decreased in a transacetylase-deficient strain, TA100 1,8-DNP6. The mutagenicity of fenitrothion was also examined by a gene mutation assay using the gene for hypoxanthine-guanine phosphoribosyltransferase (hgprt) in V79 Chinese hamster lung cells. Fenitrothion did not induce any increment of 6-thioguanine-resistant mutant cells at doses ranging from 0.01 to 0.3 mM regardless of the presence or absence of S9 mix. These results suggest that reduction of fenitrothion by a bacterial nitroreductase of TA100 to an active form is essential for the expression of the mutagenicity of fenitrothion in TA100 and that a bacterial transacetylase of TA100 also has an important role in the process of mutagenic activation. SN - 0027-5107 UR - https://www.unboundmedicine.com/medline/citation/2643032/Mutagenicity_studies_on_fenitrothion_in_bacteria_and_mammalian_cells_ DB - PRIME DP - Unbound Medicine ER -